Lack of relationship between the expression of hsp27 heat shock estrogen receptor-associated protein and estrogen receptor or progesterone receptor status in male breast carcinoma

Journal of Steroid Biochemistry and Molecular Biology

Volumn 60, Issue 5-6, 1997, Pages 277-284

  Muñoz De Toro, Mónica M ^a   Luque, Enrique H ^a  

^a UNIVERSIDAD NACIONAL DEL LITORAL   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 27; PROGESTERONE RECEPTOR;

ARTICLE; BREAST CARCINOMA; CONTROLLED STUDY; ESTROGEN METABOLISM; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; PROTEIN EXPRESSION;

ADULT; AGED; BREAST NEOPLASMS, MALE; CARCINOMA; GENE EXPRESSION; HEAT-SHOCK PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 0342617755     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(96)00221-X     Document Type: Article

References (64)

1. Henderson B. E., Ross R. and Bernstein L., Estrogens as a cause of human cancer: The Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res. 48 (1988) 246-253.
2. Sunderland M. C. and McGuire W. L., Hormones and breast cancer. Trends Endocr. Metab. 2 (1991) 72-76.
3. Ciocca D. R., Osterreich S., Chamness G. C., McGuire W. L. and Fuqua S. A. W., Heat shock protein 27000 (hsp27): biological and clinical implications. J. Natn. Cancer Inst. 85 (1993) 1558-1570.
4. Cano A., Coffer A. I., Adatia R., Millis R. R., Rubens R. D. King R. J. B., Histochemical studies with an estrogen receptor-related protein in human breast tumors. Cancer Res. 46 (1986) 6475-6480.
5. Ciocca D. R. and Luque E. H., Immunological evidence for the identity between the hsp27 estrogen-regulated heat shock protein and the p29 estrogen receptor-associated protein in breast and endometrial cancer. Breast Cancer Res. Treat. 20 (1991) 33-42.
6. Dunn D. K., Whelan R. D., Hill B. and King R. J., Relationship of hsp27 and oestrogen receptor in hormone sensitive and insensitive cell lines. J. Steroid Biochem. Molec. Biol. 46 (1993) 469-479.
7. Thomas D. B., Male breast cancer. Epidemiol Rev. 15 (1993) 220-231.
8. Muñoz de Toro M. and Luque E. H., Expression of progesterone receptor (PgRc) and hsp27 heat shock estrogen receptor-associated protein in male breast carcinoma (abstract). Breast Cancer Res. Treat. 32 (1994) 249.
9. Le Doussal V., Tubiana-Hulin M., Friedman S., Hacene K., Spyraton F. and Brunet M., Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR): an improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer 64 (1989) 1914-1921.
10. Hutter R. V. P., The role of the pathologist in breast cancer management. Cancer 66 (1990) 1363-1372.
11. Muñoz de Toro M. and Luque E. H., Effect of microwave pre-treatment on proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections. J. Histotechnol. 18 (1995) 11-16.
12. r 24000 protein in patients with carcinomas of the endometrium and cervix. Cancer Res. 49 (1989) 4298-4304.
13. Pertschuk L. P., Kim Y., Axiotis C. A., Braverman A. S., Carter A. C., Eisenberg K. B. and Braithwaite L. V., Estrogen receptor immunocytochemistry: the promise and the perils. J. Cell Biochem. 19 (1994) 134-137.
14. Press M. F. and Greene G. L., Localization of progesterone receptor with monoclonal antibodies to the human progestin receptor. Endocrinology 122 (1988) 1165-1175.
15. Allred D. C., Clark G. M., Elledge R., Fuqua S. A. W., Brown R. W., Chamness G. C., Osborne C. K. and McGuire W. L., Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J. Natn. Cancer Inst. 85 (1993) 200-206.
16. Siegel S., Nonparametric Statistics for the Behavioral Sciences. McGraw-Hill, New York, 1956.
17. Luque E. H., Muñoz de Toro M., Romero Acuña L., Langhi M. and Romero Acuña J., Molecular markers as prognostic indicators in breast cancer. Medicina (Bs. As.) 53 (1993) 151-166.
18. McGuire W. L., Tandon A. K., Allred D. C., Chamness G. C. Clark G. M., How to use prognostic factors in axillary node-negative breast cancer patients. J. Natn. Cancer Inst. 82 (1990) 1006-1015.
19. Osborne C. K., Yochmowitz M. G., Knight V. A. and McGuire W. L., The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 46 (1980) 2884-2888.
20. Clark G. M., McGuire W. L., Hubay C. A., Pearson O. H. Marshall J. S., Progesterone receptors as a prognostic factor in stage II breast cancer. N. Engl. J. Med. 309 (1983) 1343-1347.
21. Sasco A. J., Lowenfels A. B. and Pasker-de Jong P., Review article: epidemiology of male breast cancer. A meta-analysis of published case-control studies and discussion of selected aetiological factors. Int. J. Cancer 53 (1993) 538-549.
22. Everson R. B., Lippman M. E., Thompson E. B., McGuire W. L., Wittliff J. L., DeSombre E. R., Jenesen E. V., Singhakowinta A., Brooks S. C. and Neifeld J. P., Clinical correlations of steroid receptors and male breast cancer. Cancer Res. 40 (1980) 991-997.
23. Friedman M. A., Hoffman P. G., Dandolos E. M., Lagios M. D., Johnston W. H. and Siiteri P. K., Estrogen receptors in male breast cancer: clinical and pathologic correlations. Cancer 47 (1981) 134-137.
24. Morimoto T., Komaki K., Yamakawa T., Tanaka T., Oomine Y. and Konishi Y., Cancer of the male breast. J. Surg. Oncol. 44 (1990) 180-184.
25. Fox S. B., Rogers S., Day C. A. and Underwood J. C. E., Oestrogen receptor and epidermal growth factor receptor expression in male breast carcinoma. J. Pathol. 166 (1992) 13-18.
26. Ribeiro G. and Swindell R., Adjuvant tamoxifen for male breast cancer (MBC). Br. J. Cancer 65 (1992) 252-254.
27. Stalsberg H., Thomas D. B., Rosenblatt K. A., Jimenez L. M., McTiernan A., Stemhagen A., Thompson W. D., McCrea Curnen M. G., Satariano W., Austin D. F., Greenberg R. S., Key Ch., Kolonel L. and West D., Histologic types and hormone receptors in breast cancer in men: a population-based study in 282 United States men. Cancer Causes and Control 4 (1993) 143-151.
28. Kardas I., Seitz G., Limon J., Niezabitowski A., Rys J., Theisinger B., Welter C. and Blin N., Retrospective analysis of prognostic significance of the estrogen-inducible pS2 gene in male breast carcinoma. Cancer 72 (1993) 1652-1656.
29. Osborne C. K., Receptors. In Breast Diseases, 2nd edn. eds J. R. Harris, S. Hellman, Y. C. Henderson and D. W. Kinne. Lippincott, Philadelphia, 1991, pp. 301-325.
30. Elias J. M., Qiao L., Heimann A., Engellenner W. and Abel W., Paraffin embedded breast carcinomas for the immunohistochemical study of prognostic factors. J. Histotechnol. 15 (1992) 315-320.
31. Ciocca D. R. and Roig L. M. V., Estrogen receptors in human nontarget tissues: biological and clinical implications. Endocr. Rev. 16 (1995) 35-62.
32. Elledge R. M., Ciocca D. R., Langone G. and McGuire W. L., Estrogen receptor, progesterone receptor, and HER-2/neu protein in breast cancers from pregnant patients. Cancer 71 (1993) 2499-2506.
33. Navarro D., Cabrera J. J., León L., Chirino R., Fernández L., López A., Rivero J. F., Fernández P., Falcón O., Jiménez P., Pestano J., Diaz-Chico J. C. and Diaz-Chico B. N., Endometrial stromal expression of estrogen receptors, progesterone receptors and estrogen-induced srp27 (24K) suggests hormone responsiveness. J. Steroid Biochem. Molec. Biol. 41 (1992) 589-596.
34. Joshi M. G., Lee A. K. C., Loda M., Camus M. G., Pedersen C., Heatley G. J. and Hughes K. S., Male breast carcinoma: an evaluation of prognostic factors contributing to a poorer outcome. Cancer 77 (1996) 490-498.
35. Edwards D. P., Adams D. J. and McGuire W. L., Estradiol stimulates synthesis of a major intracellular protein in a human breast cancer cell line (MCF-7). Breast Cancer Res. Treat. 1 (1981) 209-223.
36. Ciocca D. R., Stati A. O. and Amprino de Castro M. M., Colocalization of estrogen and progesterone receptors with an estrogen-regulated heat shock protein in paraffin sections of human breast and endometrial cancer tissue. Breast Cancer Res. Treat. 16 (1990) 243-251.
37. Thor A., Benz Ch., Moore D., Goldman E., Edgerton S., Landry J., Schwartz L., Mayall B., Hickey E. and Weber L. A., Stress response protein (srp-27) determination in primary human breast carcinomas: clinical, histologic, and prognostic correlations. J. Natn. Cancer Inst. 83 (1991) 170-178.
38. Oesterreich S., Hilsenbeck S. G., Ciocca D. R., Allred D. C., Clark G. M., Chamness G. C., Osborne C. K. and Fuqua S. A. W., The small heat shock protein hsp27 is not an independent prognostic marker in axillary lymph node-negative breast cancer patients. Clin. Cancer Res. 2 (1996) 1199-1206.
39. Wooster R., Mangion J., Elles R., Smith S., Dowsett M., Averill D., Barrett-Lee P., Easton D. F., Ponder B. A. J. and Stratton M. R., A germline mutation in the androgen receptor gene in two brothers with breast cancer and Reifenstein syndrome. Nature Genet. 2 (1992) 132-134.
40. Lobaccaro J. M., Lumbroso S., Belon C., Galtier-Dereure F., Bringer J., Lesimple T., Namer M., Cutuli B. F., Pujol H. and Sultan Ch., Androgen receptor gene mutation in male breast cancer. Hum. Molec. Genet. 2 (1993) 1799-1802.
41. Fuqua S. A. W., Fitzgerald S. D., Chamness G. C., Tandon A. K., McDonnell D. P., Nawaz Z., O'Malley B. W. and McGuire W. L., Variant human breast tumor estrogen receptor with constitutive transcriptional activity. Cancer Res. 51 (1991) 105-109.
42. Horwitz K. B., Mechanisms of hormone resistance in breast cancer. Breast Cancer Res. Treat. 26 (1993) 119-130.
43. Osborne C. K. and Fuqua S. A. W., Mechanisms of tamoxifen resistance. Breast Cancer Res. Treat. 32 (1994) 49-55.
44. Sasano H., Nagura H., Harada N., Goukon Y. and Kimura M., Immunolocalization of aromatase and other steroidogenic enzymes in human breast disorders. Hum. Pathol. 25 (1994) 530-535.
45. Pasqualini J. R., Chetrite G., Nguyen B.-L., Maloche C., Delalonde L., Talbi M., Feinstein M.-C., Blacker C., Botella J. Paris J., Estrone sulfate-sulfatase and 17β-hydroxysteroid dehydrogenase activities: a hypothesis for their role in the evolution of human breast cancer from hormone-dependence to hormone-independence. J. Steroid Biochem. Molec. Biol. 53 (1995) 407-412.
46. Sasano H., Kimura M., Shizawa S., Kimura N. and Nagura H., Aromatase and steroid receptors in gynecomastia and male breast carcinoma: an immunohistochemical study. J. Clin. Endocr. Metab. 81 (1996) 3063-3067.
47. Elledge R. M., McGuire W. L. and Osborne C. K., Prognostic factors in breast cancer. Semin. Oncol. 19 (1992) 244-252.
48. Donegan W. L., Prognostic factors: stage and receptor status in breast cancer. Cancer 70 (1992) 1755-1764.
49. Sluyser M., Role of estrogen receptor variants in the development of hormone resistance in breast cancer. Clin. Biochem. 25 (1992) 407-414.
50. Seymour L., Bezwoda W. R. and Meyer K., Tumor factors for prognosis in metastatic breast cancer: the presence of p24 predicts for response to treatment and duration of survival. Cancer 66 (1990) 2390-2394.
51. Tetu B., Brisson J., Landry J. and Huot J., Prognostic significance of heat-shock protein-27 in node-positive breast carcinoma: an immunohistochemical study. Breast Cancer Res. Treat. 36 (1995) 93-97.
52. Harris J. R., Morrow M. and Bonadona G., Cancer of the breast. In Cancer: Principles and Practice of Oncology, 4th edn, eds V. T. DeVita, S. Hellman and S. A. Rosenberg. Lippincott, Philadelphia, 1993, pp. 1264-1332.
53. Guinee V. F., Olson H. and Moller T., The prognosis of breast cancer in males. Cancer 71 (1993) 154-161.
54. Ciatto S., Iossa A. and Bonardi R., Male breast carcinoma: review of a multicenter series of 150 cases. Tumori 76 (1990) 555-558.
55. Heller K. S., Rosen P. P. and Schottenfeld D., Male breast cancer: a clinicopathologic study of 97 cases. Ann. Surg. 188 (1978) 60-65.
56. Salvadori B., Saccozzi R., Manzari A., Andreola S., Conti R. A., Cusumano F. and Grassi M., Prognosis of breast cancer in males: an analysis of 170 cases. Eur. J. Cancer 30 (1994) 930-935.
57. Love S. and King R. J. B., A 27 kDa heat shock protein that has anomalous prognostic powers in early and advanced breast cancer. Br. J. Cancer 69 (1994) 743-748.
58. Miron T., Vancompernolle K. and Vandekerckhove J., A 25-kDa inhibitor of actin polymerization is a low molecular mass heat shock protein. J. Cell Biol. 114 (1991) 255-261.
59. Borgen P. I., Wong G. Y., Vlamis V., Potter C., Hoffmann B. Kinne D. W., Current management of male breast cancer: a review of 104 cases. Ann. Surg. 215 (1992) 451-457.
60. Fox S. B., Day C. A. and Rogers S., Lack of c-erbB-2 oncoprotein expression in male breast carcinoma. J. Clin. Pathol. 44 (1991) 960-961.
61. Gattuso P., Reddy V. B., Green L., Castelli M., Haley D. and Herman Ch., Prognostic significance of DNA ploidy in male breast carcinoma: a retrospective analysis of 32 cases. Cancer 70 (1992) 777-780.
62. Blin N., Kardas I., Welter C., Rys J., Niezabitowski A., Limon J. and Seitz G., Expression of the c-erbB2 proto-oncogene in male breast carcinoma: lack of prognostic significance. Oncology 50 (1993) 408-411.
63. Rogers S., Day C. A. and Fox S. B., Expression of cathepsin D and estrogen receptor in male breast carcinoma. Hum. Pathol. 24 (1993) 148-151.
64. Hatschek T., Wingren S., Carstensen J. and Hultbom R., DNA content and S-phase fraction in male breast carcinomas. Acta Oncol. 33 (1994) 609-613.